J Nathaniel Diehl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5893437/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. Advances in Cancer Research, 2022, 153, 101-130.	5.0	8
2	Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2022, 21, 762-774.	4.1	9
3	Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell Reports, 2021, 35, 109291.	6.4	15
4	The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer. Journal of Biological Chemistry, 2021, 297, 101335.	3.4	14
5	CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell Reports, 2021, 37, 110060.	6.4	14
6	Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Cancer Discovery, 2020, 10, 104-123.	9.4	131
7	Gain-of-Function <i>RHOA</i> Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. Cancer Discovery, 2020, 10, 288-305.	9.4	91
8	Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. Cell Reports, 2020, 31, 107764.	6.4	69
9	Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature Medicine, 2019, 25, 628-640.	30.7	476